Short acting beta 2 agonist
Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease
... Overall completeness and applicability of evidence The lack of clear differences in effect between the treatment groups for many of the outcomes may be due to the relatively short treat- ment duration, with four ...
47
Indacaterol: a new once daily long-acting beta<sub>2</sub> adrenoceptor agonist
... daily beta 2 agonists, formoterol and salmeterol, and the once daily anticholinergic, ...to short-acting agents with multiple daily ...daily beta 2 agonist as compared to ...
5
Efficacy and safety of the long-acting β<sub>2</sub>-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
... anticholinergics throughout the study, as needed, and the short-acting β -adrenergic salbutamol (100 µ g) was allowed as rescue medication, if required. The study was approved by local ethics committees and ...
11
Effects of two inhaled corticosteroid/long-acting beta-agonist combinations on small-airway dysfunction in mild asthmatics measured by impulse oscillometry
... in 2- to 5-year-old children with reversible airflow obstruction, assessed by forced oscil- lation ...the short-acting beta agonist (SABA) albuterol at ...adults, 2 it has not ...
8
Effects of Two Inhaled Corticosteroid/Long-Acting Beta-Agonist Combinations on Small-Airway Dysfunction in Mild Asthmatics Measured by Impulse Oscillometry
... in 2- to 5-year-old children with reversible airflow obstruction, assessed by forced oscil- lation ...the short-acting beta agonist (SABA) albuterol at ...adults, 2 it has not ...
9
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β<sub>2</sub>-agonist fixed-dose combination: RE<sup>2</sup>SPOND rationale and study design
... β 2 -agonist; LAMA, long-acting muscarinic antagonist; REACT, Roflumilast and Exacerbations in patients receiving Appropriate Combination Therapy; SAMA, short-acting muscarinic ...
8
Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease (Review)
... patients experiencing exacerbations during the study period with- out reporting the number of withdrawals due to exacerbation. In Aaron 2007 exacerbation was defined as a sustained worsening of the patient’s respiratory ...
41
Association of blood eosinophils and plasma periostin with FEV<sub>1</sub> response after 3-month inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist treatment in stable COPD patients
... for 2 weeks, an inhaled LABA, or long-acting muscarinic antagonist for 2 days, an inhaled short-acting β 2-agonist or inhaled short-acting antich- olinergic ...
8
Combination formoterol and inhaled steroid versus beta(2)-agonist as relief medication for chronic asthma in adults and children (Review)
... 2. The corticosteroid is co-delivered with formoterol and compared with terbutaline in most of the studies we included. It is true that both groups of participants receive reliever medications, but essentially the ...
58
High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis
... The over-prescription of SABA with insufficient con- troller medication prescription remains frequent. In a 1-year study on asthma patients from primary care healthcare records, 6.6% of the SABA over-users were not on ...
10
EFFECT OF GLY 16 ARG SINGLE NUCLEOTIDE POLYMORPHISM ON AGONIST BINDING TO BETA 2 ADRENERGIC RECEPTOR – A STRUCTURAL PHARMACOGENOMIC APPROACH
... β 2 - adrenergic agonists 9-11 . The common non synonymous SNPs of the β 2 adrenoceptor that tend to alter the protein conformation are Gly16Arg, Glutamate 27 Glutamine (Glu27Gln), Valine 34 Methionine ...
10
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β<sub>2</sub>-adrenoreceptor agonist (uLABA)
... β 2 -adrenoceptor agonists, while in COPD guidelines both β 2 -agonist and muscarinic antagonist bronchodilators are recommended, alone or in ...
10
Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
... It is infrequent that the lack of asthma control is a direct consequence of a condition of drug-resistant disease. It is more likely that an uncontrolled condition is related to the u[r] ...
10
Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
... Notes: Other 1, argentina, Chile, Mexico, Peru, Philippines; Other 2, australia, Canada, south africa. The most prevalent region in each cluster is shown in bold. Abbreviation: BMI, body mass index. Discussion ...
12
Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
... 1); 2) the initial treatment was not administered at our hospital (n =232); 3) ICS therapy was given during the observation period, and comorbid asthma was diagnosed by a respiratory specialist (n =316); 4) a ...
8
Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
... β2-adrenoceptor agonist (LABA)/long-acting muscarinic antagonist (LAMA) combinations induce a strong synergistic bronchodilatory effect in human isolated ...
7
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
... We chose to stratify our population by a blood eosinophil count of 2%, as previous publications identi fied the high sensitivity of this cut-off point for the presence of a raised sputum eosinophil count. 12 13 In ...
8
Comprehensive assessment of the safety of olodaterol 5 mu g in the Respimat (R) device for maintenance treatment of COPD: comparison with the long-acting beta(2)-agonist formoterol
... β 2 -agonists as well as those included in the olodaterol and formoterol ...β 2 -agonists, including cardiovascular events, as well as administration-related ...β 2 -agonist safety pro file ...
6
Effect of background long-acting beta<sub>2</sub>-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
... In addition, prior use of TIO may have contributed to the perception and reporting of TEAEs, as ~ 30% of subjects were treated with TIO for 2 years prior to randomization. 12 Due to their individual mechanisms of ...
13
Long-acting beta-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
... Overall asthma control. All of the following: no asthma-related hospital admission; no emergency room or outpatient attendance for asthma; no prescription for OCS or antibiotic with evidence of respiratory consultation; ...
33